natgillin/translations-raw huggingface dataset:
The salt according to claim 3, further characterized in that the compound has an X-ray powder diffraction pattern containing at least peaks with 2-theta values at 8,9°, 10.9°, 18°, 25.5°, 15.5° and 21.7° measured using CuKa radiation, 
Sol prema zahtjevu 3, nadalje naznačena time da spoj ima uzorak difrakcije X-zraka na prahu koji sadrži barem vrške sa 2-theta vrijednostima pri 8,9°, 10.9°, 18°, 25.5°, 15.5° i 21.7° mjereno korištenjem CuKa zračenja.
The salt according to claim 4, further characterized in that the compound has an X-ray powder diffraction pattern containing at least peaks with 2-theta values at 8.9°, 10.9°, 18°, 25.5°, 15.5°, 21.7, 21.2°, 24.1° and 25.9° measured using CuKa radiation. 
Sol prema zahtjevu 4, nadalje naznačena time da spoj ima uzorak difrakcije X-zraka na prahu koji sadrži barem vrške sa 2-theta vrijednostima pri 8.9°, 10.9°, 18°, 25.5°, 15.5°, 21.7, 21.2°, 24.1° i 25.9° mjereno korištenjem CuKa zračenja.
A compound according to claim 5, characterized by an X ray diffraction pattern essentially as defined in Figure 3 and/or in Table 3: Table 3 
Spoj prema zahtjevu 5, naznačen time da je uzorak difrakcije X-zraka u osnovi kako je definirano na slici 3 i/ili u Tabeli 3: Tabela 3 [image]
A process for the manufacture of N -(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide substantially in the form of Form 1 which comprises: 
Postupak za proizvodnju N-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida u osnovi u obliku Oblika 1 naznačen time da sadrži:
The process according to claim 9 or claim 10 wherein the acid is acetic acid. 
Postupak prema zahtjevu 9 ili zahtjevu 10 naznačen time da kiselina je octena kiselina.
wherein each RC and RD is independently selected from the group consisting of hydrogen and C1-4alkyl; 
pri čemu se RC i RD neovisno odabiru iz skupine koju sačinjavaju vodik i C1-4alkil;
wherein RN is selected from the group consisting of hydrogen and C1-4alkyl; 
pri čemu se RN odabire iz skupine koju sačinjavaju vodik i C1-4alkil;
a is an integer from 0 to 3; 
a je prirodni broj od 0 do 3;
A compound as In Claim 1 wherein R0 is selected from the group consisting of hydrogen and methyl; R11s selected from the group consisting of hydrogen, hydroxy, methyl, trifluoromethyl, methoxy and methyl-carbonyl; 
se R0 odabire iz skupine koju sačinjavaju vodik i metil; se R1 odabire iz skupine koju sačinjavaju vodik, hidroksi, metil, trifluorometil, metoksi i metil-karbonil;
wherein the aryl, whether alone or as part of a substituent group is optionally substituted with one to two substituent independently selected from the group consisting of C1-4alkyl, C1-4alkoxy, halogen, hydroxy, carboxy, amino, C1-4alkylamino, di(C1-4alkyl)amino, cyano and nitro; 
pri čemu je aril, bilo pojedinačan ili kao dio zamjenske skupine opcionalno supstituiran sa jednim ili dva supstituenta koji se neovisno odabiru iz skupine koju sačinjavaju C1-4alkil, C1-4alkoksi, halogen, hidroksi, karboksi, amino, C1-4alkilamino, di(C1-4alkil)amino, cijano i nitro;
is selected from the group consisting of phenyl and 2-methoxyphenyl; a is 0; 
se R3 odabire iz skupine koju sačinjavaju fenil i 2-metoksifenil; je a 0;
b is an integer from 0 to 1; 
je b prirodni broj od 0 do 1;
is -(O)-; is selected from the group consisting of phenyl, 2-fluorophenyl and 2-methoxy-phenyl; 
se R3 odabire iz skupine koju sačinjavaju fenil, 2-fluorofenil i 2-metoksi-fenil; je a 0;
The compound of Claim 15, wherein the disorder mediated by β-secretase is selected from the group consisting of Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid. 
Spoj prema Zahtjevu 15, naznačen time da se poremećaj posredovan β-sekretazom odabire iz skupine koja se sastoji od Alzheimerove bolesti (AD), blagog kognitivnog poremećaja, senilnosti, demencije, demencije sa Lewyjevim tjelešcima, Downovog sindroma, demencije povezane sa Parkinsonovom bolesti i demencije povezane sa beta-amiloidom.
wherein each RL and RM is independently selected from the group consisting of hydrogen and C1-4alkyl; 
pri čemu se RL i RM neovisno odabiru iz skupine koju sačinjavaju vodik i C1-4alkil;
wherein each RS and RT is independently selected from the group consisting of hydrogen and C1-4alkyl; 
pri čemu se RS i RT neovisno odabiru iz skupine koju sačinjavaju vodik i C1-4alkil;
wherein each RV and RV is independently selected from the group consisting of hydrogen and C1-4alkyl; alternatively RV and RW are taken together with the N atom to which they are bound to form a 5 to 6 membered saturated, partially unsaturated or aromatic ring structure; 
pri čemu se svaki RV i RW neovisno odabiru iz skupine koju sačinjavaju vodik i C1-4alkil; alternativno RV i RW, zajedno sa dušikovim atomom na kojeg su vezani, tvore 5-ero do 6-eročlani zasićeni, djelomično nezasićeni ili aromatični prsten;
The process of claim 1 characterised by further comprising a purification step (3) to further purify the overhead unabsorbed component gas, the flashed overhead product stream, or both. 
Proces prema patentnom zahtjevu 1, naznačen time, da nadalje sadrži stupanj pročišćavanja (3) da se dalje pročisti vršni neapsorbirani komponentni plin, fleširana vršna struja produkta ili oboje.
The process of claim 5, characterised in that an absorber/regeneration system employing a circulating solvent is used in the purification step. 
Proces prema patentnom zahtjevu 5, naznačen time, da se primjenjuje sistem apsorbera/regeneracije koji koristi optočno otapalo u stupnju pročišćavanja.
The process of claim 5, characterised in that adsorption, membrane, incineration or other technologies are used in the purification step. 
Proces prema patentnom zahtjevu 5, naznačen time, da se u stupnju pročišćavanja koriste adsorpcijska, membranska, incineracijska ili druge tehnologije.
The process of claim 9, characterised in that the multi-component gas stream comprises natural gas, coal gas, refinery gas or gas from chemical plants. 
Proces prema patentnom zahtjevu 9, naznačen time, da višekomponentna plinska struja sadrži prirodni plin, gradski plin, rafinerijski plin ili plin iz kemijskih postrojenja.
The process of claim 9, characterised in that the product stream comprises methane. 
Proces prema patentnom zahtjevu 9, naznačen time, da struja produkta sadrži metan.
The process of claim 9, characterised in that the external solvent is selected from the group consisting of paraffinic solvents, naphthenic solvents, aromatic solvents and specially mixed solvents. 
Proces prema patentnom zahtjevu 9, naznačen time, da se vanjsko otapalo odabire iz skupine koja se sastoji od parafinskih otapala, naftenskih otapala, aromatskih otapala i posebno miješanih otapala.
The process of claim 9, characterised in that the extractor vessel (5) is a tower with internals to promote mass transfer. 
Proces prema patentnom zahtjevu 9, naznačen time, da je ekstraktorska posuda (5) jedan toranj s unutarnjom opremom koja pospješuje transfer mase.
The process of claim 9, characterised in that the level control instrumentation on the vessels upstream of the surge vessel act as downstream controllers and the level control instrumentation on the vessels downstream of the surge vessel act as upstream controllers. 
Proces prema patentnom zahtjevu 9, naznačen time, da instrumentacija kontrole razine na posudama koje su suprotno smjeru struje od sabirne posude djeluje kao kontroieri niz struju, a instrumentacija kontrole razine na posudama niz struju od sabirne posude djeluje kao kontroieri suprotno smjeru struje.
The process of claim 3, characterised in that the operating pressure of the flash vessels is increased to reduce vaporization of a contaminant. 
Proces prema patentnom zahtjevu 3, naznačen time, da se radni pritisak posuda za isparavanje povećava da bi se smanjilo isparavanje kontaminanta.
The process of claim 8, characterised in that the pressure of the last flash vessel is below atmospheric pressure. 
Proces prema patentnom zahtjevu 8, naznačen time, da je pritisak posljednje posude za isparavanje ispod atmosferskog pritiska.
A compound according to Formula I: wherein M represents the macrolide subunit of the substructure II: wherein R1, R2, R3, R4 and R5 are, chosen independently of each other, from the group consisting of hydrogen, C1-C4alkyl, alkanoyl, alkoxycarbonyl, arylmethoxycarbonyl, aroyl, arylalkyl, alkylsilyl and alkylsilylalkoxyalkyl; 
[image], gdje M predstavlja makrolidnu podjedinicu podstrukture II: [image], gdje, R2, R3, R4 i R5 se, međusobno neovisno, bira iz skupine koju čine vodik, C1-C4alkil, alkanoil, alkoksikarbonil, arilmetoksikarbonil, aroil, arilalkil, alkilsilil i alkilsililalkoksialkil;
symbols m and n, independently, are whole numbers from 0 to 4; 
simboli m i n, neovisno, su cijeli brojevi, od 0 do 4;
wherein "alkyl", unless otherwise stated, means a linear or branched saturated monovalent hydrocarbon radical of one to ten carbon atoms, which may be substituted with one up to five substituents including halogen, hydroxy, alkoxy, acyl, acylamino, cyano, amino, N-(C1-C4)alkylamino, N,N-di(C1-C4-alkyl)amino, thiocarbonylamino, acyloxy, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, heteroaryl, aryloxy, aryloxyaryl, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, cycloalkoxy, heteroaryloxy, heterocyclyloxy, and oxycarbonylamino; and the present definition of alkyl carries over to other groups having an alkyl moiety such as alkoxy or alkanoyl; 
gdje "alkil", ukoliko se ne navede drugačije, znači nerazgranati ili razgranati zasićeni jednovalentni ugljikovodični radikal s 1 do 10 atoma ugljika, koji može biti supstituiran s jednim do pet supstituenata, uključujući halogen, hidroksi, alkoksi, acil, acilamino, cijano, amino, N-(C1-C4)alkilamino, N,N-di(C1-C4-alkil)amino, tiokarbonilamino, aciloksi, amidino, alkilamidino, tioamidino, aminoacil, aminokarbonilamino, aminotiokarbonilamino, aminokarboniloksi, aril, heteroaril, ariloksi, ariloksiaril, nitro, karboksil, karboksilalkil, s karboksilom supstituirani alkil, karboksil-cikloalkil, s karboksilom supstituirani cikloalkil, karboksilaril, s karboksilom supstituirani aril, karboksilheteroaril, s karboksilom supstituirani heteroaril, karboksilheterocikl, s karboksilom supstituirani heterocikl, cikloalkil, cikloalkoksi, heteroariloksi, heterocikliloksi, te oksikarbonilamino; ova definicija alkila vrijedi i za druge skupine koje sadrže alkilni ostatak, poput alkoksi ili alkanoila;
"cycloalkyl" means a cyclic group having 3-8 carbon atoms having a single ring optionally fused to an aryl or heteroaryl group, and which may be substituted as specified for "aryl" below; 
"cikloalkil" znači prstenasta skupina s 3 do 8 atoma ugljika, s jednim prstenom, izborno kondenziran s arilnom ili heteroarilnom skupinom, te koji može biti supstituiran kao što je specificirano za "aril", niže;
"heteroaryl" means a monocyclic or a bicyclic aromatic hydrocarbon ring having from 2 to 10 carbon atoms and from 1 to 4 heteroatoms, such as O, S or N, and which may optionally be fused to another heteroaryl, aryl or aliphatic cyclic group, and which may be substituted with the same substituents as specified for aryl above; 
"heteroaril" znači monociklički ili biciklički aromatski ugljikovodički prsten s 2 do 10 atoma ugljika i od 1 do 4 heteroatoma, poput O, S ili N, te koji može izborno biti kondenziran s drugim heteroarilom, arilom ili alifatskom prstenastom skupinom, te koji može biti supstituiran s istim supstituentima kao što je specificirano za aril, gore;
A compound according to Claim 1 wherein D is a steroid of the substructure IV: wherein Ra, Rb, are chosen independently of each other from the group consisting of hydrogen and halogen; 
Spoj u skladu s patentnim zahtjevom 1, gdje D je steroid podstrukture IV: [image], gdje Ra i Rb se, međusobno neovisno, bira iz skupine koju čine vodik i halogen;
Rf is chosen from the group consisting of hydrogen, hydroxyl group, halogen or forms a carbonyl group with the carbon atom to which it is linked; 
Rf se bira iz skupine koju čine vodik, hidroksilna skupina, halogen, ili tvori karbonilnu skupinu s atomom ugljika na kojeg je vezan;
Rd and Re, are chosen independently from the group consisting of hydrogen, hydroxy, C1-4alkoxy or together with the pertaining C-atoms represent 1,3-dioxolane ring which can be additionally alkyl or alkenyl mono or di-substituted; and Rj is chosen from the group consisting of hydrogen and chlorine; 
Rd i Re se neovisno bira iz skupine koju čine vodik, hidroksi, C1-4alkoksi, ili, zajedno s pripadajućim C-atomima, predstavlja 1,3-dioksolanski prsten, koji može biti daljnje mono- ili disupstituiran s alkilom ili alkenilom; i Rj se bira iz skupine koju čine vodik i klor;
A compound according to claim 2 wherein R1, R2, R3, R4 and R5 are each independently chosen from the group consisting of hydrogen, methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl and tert-butyl. 
Spoj u skladu s patentnim zahtjevom 2, gdje R1, R2, R3, R4 i R5 se svakog neovisno bira iz skupine koju čine vodik, metil, etil, propil, iso-propil, butil, sec-butil i tert-butil.
The compound according to claim 6 wherein m=1 n=1 and Q is CH2. 
Spoj u skladu s patentnim zahtjevom 6, gdje m = 1, n = 1, a Q je CH2.
A compound according to claim 22 wherein the nonsteroidal anti-inflammatory subunit is chosen from the group consisting of indomethacin, flufenamic acid, flunixin and theophylline. 
Spoj u skladu s patentnim zahtjevom 22, gdje nesteroidnu protuupalnu podjedinicu se bira iz skupine koju čine indometacin, flufenaminska kiselina, fluniksin i teofilin.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time, ili povezana s neželjenim upalnim imunosnim odgovorom i svim bolestima i stanjima induciran ili povezanim s prekomjernim lučenjem TNF-a i IL-1.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory conditions and immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissue. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
Use according to claim 35, wherein said inflammatory conditions and immune disorders are selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowel, skin, and heart. 
Upotreba spoja u skladu s patentnim zahtjevom 35, gdje navedena upalna stanja i imunosne poremećaje se bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože te srca.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated by excessive unregulated production of cytokines or inflammatory mediators. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje bolesti, poremećaja i stanja, naznačena time, ili povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
one or more containment sections (2, 4, 6, 8, 10, 12) for filling material in which plant material can be cultivated, 
jednu ili više ograđenih sekcija (2, 4, 6, 8, 10, 12) za punjenje materijalom u kojem se može kultivirati biljni materijal,
connecting means (30, 32) engaged with the frame means in order to connect those frame means to one another, and 
vezna sredstva (30, 32) zakvačena sa sredstvima okvira da bi se ta sredstva okvira međusobno povezala, i
a plurality of wall means (40) engaged with the frame means in such a manner as to define at least one pair of lateral walls of the one or more containment sections, 
više sredstava stijenki (40) zakvačenih sa sredstvima okvira na takav način da se odredi barem jedan par bočnih stijenki jedne ili više ograđenih sekcija,
the lateral walls comprise panels (40) of electrically welded netting composed of double horizontal wires (42) and single vertical wires (44). 
bočne stijenke sadrže panele (40) od električki zavarene mreže sastavljene od dvostrukih horizontalnih žica (42) i jednostrukih vertikalnih žica (44).
A structure according to claim 1, characterized in that the frame means comprise a plurality of support frames (20), the support frames of end containment sections (2, 4, 10, 12) being of lower height compared to those_of_central containment sections (6, 8). 
Konstrukcija u skladu s patentnim zahtjevom 1, naznačena time, da sredstva okvira sadrže više potpornih okvira (20), a potporni okviri krajnjih ograđenih sekcija (2, 4, 10, 12) su niže visine u usporedbi s onima od središnjih ograđenih sekcija (6, 8).
the netting panels (40) of electrically welded netting being composed of double horizontal wires (42) and single vertical wires (44). 
mrežni paneli (40) su od električki zavarene mreže sastavljene od dvostrukih horizontalnih žica (42) i jednostrukih vertikalnih žica (44).
A container according to claim 7, wherein the liquid or the gas comprises at least CO2. 
Spremnik prema zahtjevu 7, naznačen time, da njegova tekućina ili plin sadrži najmanje CO2.
A container according to claim 7 or 8, wherein the pressure control device comprises a gas holder (15, 16) in which a pressure gas is included at a first pressure while in the pressure control chamber, a second pressure prevails which is lower than the first pressure and comprising a mechanism (32) for opening and/or closing a gas supply opening of the gas holder, designed for having pressure gas escape in a controlled manner from the gas holder to the container to such an extent that the pressure in the container becomes approximately equal to or higher than the second pressure. 
Spremnik prema zahtjevu 7 ili 8, naznačen time, da uređaj za upravljanje tlakom sadrži nosač plina (15, 16) u kojem je uključen plin na prvom tlaku, dok je u upravljačkoj tlačnoj komori drugi tlak prevagnuo, koji je niži od prvoga tlaka, zatim da sadrži mehanizam (32) za otvaranje i/ili zatvaranje otvora za dovod plina u plinskom nosaču, koji je konstruiran za otpuštanje stlačenog plina na kontrolirani način iz plinskog nosača u spremnik, do te mjere da tlak u spremniku postaje otprilike isti ili viši od drugoga tlaka.
manufacturing a beverage container (2); 
proizvodnja spremnika pića (2);
introducing beverage (3) and the pressure control device (17) into the beverage container (2); 
stavljanje pića (3) i uređaja za upravljanje tlakom (17) u spremnik pića (2);
sealing the beverage container; 
brtvljenje spremnika pića;
before the beverage and the pressure control device are brought into contact, the pressure control device is stored at atmospheric conditions. 
pri čemu prije nego piće i uređaj za upravljanje tlakom dođu u dodir, uređaj za upravljanje tlakom se skladišti u atmosferskim uvjetima.
is hydrogen or a radical of formula wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5; and R11 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R11 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; 
je vodik ili radikal formule [image] pri čemu s je cijeli broj jednak nuli, 1, 2, 3 ili 4; r je cijeli broj jednak 1, 2, 3, 4 ili 5; i R11 je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R11 radikala mogu se zajedno uzeti da sa fenilnim prstenom na kojeg su vezani tvore naftil;
provided that when R7 is hydrogen then said hydrogen may also be replaced by the radical. 
uz uvjet da kada je R7 vodik tada navedeni vodik može se također zamijeniti sa [image] radikalom.
A compound according to claim 1 provided that when R6 is other than hydrogen then R7 is hydrogen and when R7 is other than hydrogen then R6 is hydrogen. 
Spoj prema patentnom zahtjevu 1, naznačen time da kada je R6 različit od vodika tada je R7 vodik i kada je R7 različit od vodika tada je R6 vodik.
A compound according to claim 1 or 2 wherein R2 is hydrogen; alkyl; alkyloxy optionally substituted with amino or mono or di(alkyl)amino or a radical of formula wherein Z is CH2, CH-R10, O, S, N-R10 and t is an integer equal to 1 or 2 and the dotted line represents an optional bond; mono or di(alkyl)amino; Ar; Het or a radical of formula wherein Z is CH2, CH-R10, O, S, N-R10; t is an integer equal 1 or 2; and the dotted line represents an optional bond. 
Spoj prema patentnom zahtjevu 1 ili 2, naznačen time da R2 je vodik; alkil; alkiloksi po izboru supstituiran sa amino ili mono ili di(alkil)amino ili radikalom formule [image] pri čemu Z je CH2, CH-R10, O, S, N-R10 i t je cijeli broj jednak 1 ili 2, i isprekidana crta predstavlja vezu po izboru; mono ili di(alkil)amino; Ar; Het ili radikal formule [image] pri čemu Z je CH2, CH-R10, O, S, N-R10; t je cijeli broj jednak 1 ili 2; i isprekidana crta predstavlja vezu po izboru.
is a radical of formula wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5; and R11 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R11 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; 
je radikal formule [image] pri čemu s je cijeli broj jednak nuli, 1, 2, 3 ili 4; r je cijeli broj jednak 1, 2, 3, 4 ili 5; i R11 je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R11 radikala mogu se zajedno uzeti da sa fenilnim prstenom na kojeg su vezani čine naftil;
A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 12. 
Kompozit naznačen time da sadrži farmaceutski prihvatljiv nosač i, kao aktivni sastojak, terapeutski djelotvornu količinu spoja kako je definirano u bilo kojem od patentnih zahtjeva 1 do 12.
reacting an intermediate of formula (II) with in the presence of a suitable catalyst, a suitable solvent and a suitable base, wherein W1 represents a suitable leaving group and wherein R1, R3 to R7, p, q and X are defined as in claim 1; 
reakciju intermedijera formule (II) sa [image] u prisutnosti pogodnog katalizatora, pogodnog otapala i pogodne baze, [image] pri čemu W1 predstavlja pogodnu odlaznu skupinu i pri čemu su R1, R3 do R7, p, q i X kako je definirano u patentnom zahtjevu 1;